Similarly, GSE treatment led to the downregulation of two transcription factors: cyclic AMP-responsive element-binding protein-1 (CREB-1) and glucocorticoid receptor (GR), which upregulate the aromatase gene expression through the promoters I.3/II and I.4 in breast cancer [33]. Here, CYP19A1 is linked to breast carcinoma.